Immucell Corp ICCC
Immucell Corp (Nasdaq: ICCC) is an infectious disease animal health company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| First Defense product line (USDA-licensed boluses and gels; FDA-regulated feed-ingredient powders) | calf scours prevention | biologic-other | NA_NON_THERAPEUTIC |
| Re-Tain (purified nisin) | subclinical mastitis in lactating cows (animal drug; FDA NADA Incomplete Letter Dec 2025, manufacturing development ceased, to be licensed/partnered) | small molecule | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.